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Introduction: Intrauterine androgens of a male fetus may influence the female fetus in opposite-
sex twin pairs. Because female intrauterine overexposure to androgens could lead to polycystic
ovary syndrome (PCOS), theprevalenceofPCOS shouldbehigher inwomenfromopposite-sex twin
pairs. Therefore, the aim of the current study was to evaluate the prevalence of PCOS in women
from opposite-sex twin pairs compared to women from same-sex twin pairs, sisters, and female
spouses of twins.
Subjects andMethods:Data from1325monozygotic twins, 1191 dizygotic twins (711women from
same-sex twin pairs and 480 women from opposite-sex twin pairs), 745 sisters of twins, and 218
spouses ofmale twinswere evaluated. PCOSwas defined as less than nine naturalmenstrual cycles
a year combined with either hirsutism or acne. The prevalence of PCOS was compared using a 2
test. Binary logistic regressionanalyseswere conducted to test for confoundingeffects of smoking,
age, and body mass index.
Results:No significant differences in PCOSprevalencewere foundbetweenwomen from same-sex
twin pairs (either monozygotic or dizygotic), opposite-sex twin pairs, sisters, and spouses.
Conclusion:TheprevalenceofPCOS isnotdifferent inwomenfromopposite-sexandsame-sex twin
pairs, singleton sisters, or spouses. This indicates that possible androgen exposure of the female
fetus, caused by a shared intrauterine environment with a male fetus, does not result in PCOS-like
traits. (J Clin Endocrinol Metab 94: 1987–1990, 2009)
There are some indicators that intrauterine androgens of amale fetus may influence females of opposite-sex twin
pairs. Animal studies show that sex hormones can diffuse
through the fetal membranes and the amniotic fluid and there-
fore are able to influence the developing fetus. Studies in mam-
mals show even permanently altered hormone levels, reproduc-
tive organs, aggressive behavior, and susceptibility to endocrine
disruptionwithin femaleswhowere positionedbetweenmales in
utero. This intrauterine effect is attributable to the transfer of
testosterone from male fetuses to adjacent female fetuses (1–3).
It has been shown that intrauterine overexposure to androgens
in the nonhuman primate leads to female offspring with poly-
cystic ovary syndrome (PCOS)-like traits (2, 4).
In humans, females of an opposite-sex twin pair had fewer
offspring and therefore a reduced lifetime fecundity in a histor-
ical data set collected from twins born in Finland between 1734
and1888.This study suggested that females (n31)bornaspart
of an opposite-sex twin pair were 25% less likely to reproduce
than female twins (n 35) born as part of a same-sex twin pair
(5). Acquisition of testosterone from the male co-twin was sug-
gested as a possible cause. However, Medland et al. (6) showed
that in modern populations from Australia, The Netherlands,
and the United States there were no reproduction differences
among female twins from same-sex (n 1979) and opposite-sex
(n  913) dizygotic (DZ) pairs. In all three samples, there were
no differences in the number of children, age of first pregnancies,
or psychological femininity between women from same-sex or
opposite-sex twin pairs (6).
If women of opposite-sex twin pairs have reduced fecundity
through androgen excess produced by themale co-twin and such
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overexposure causes PCOS-like symptoms, then a higher prev-
alence of PCOS among the females of opposite-sex twin pairs is
expected.
PCOS is defined, according to the Rotterdam criteria, by at
least two of the following criteria: oligo- or anovulation, clinical
and/or biochemical signs of hyperandrogenism (defined as acne/
hirsutism or elevated serum androgen levels), or polycystic ova-
ries on ultrasound (defined as a volume10 cc or12 follicles
smaller than 10 mm in both ovaries) (7). For this study, data on
oligo- or anovulation, acne, and hirsutism were obtained by
self-report.
The aim of the current study was to evaluate the prevalence
of PCOS in women of an opposite-sex twin cohort compared
with females from same-sex twin pairs, singleton sisters, and
biologically unrelated women (spouses of male twins).
Subjects and Methods
Subjects
This study is part of an ongoing twin family study on health-related
behavior inparticipants ofTheNetherlandsTwinRegister (8, 9). For this
study, data of the 2000 survey were used (n  4228). Subjects were
excluded when sufficient data on menstrual cycle, acne, or hirsutism
weremissing (n749).A total of 1325 femalemonozygotic (MZ) twins,
1191 DZ twins (711 women from same-sex twin pairs and 480 women
from opposite-sex twin pairs), 745 sisters of twins, and 218 spouses of
male twins were included in the study. Twin zygosity was based on
(longitudinal) questionnaire data or, when available, on DNA typing.
Agreement between zygosity based on questionnaire data and zygosity
based on DNA results is 96%. PCOS was defined as oligomenorrhea
combined with hyperandrogenism (10). Information about cycle irreg-
ularity, excessive hair growth, and acnewas obtained from the following
questions: 1)Whatwas thenumberofmenstrual cycles per yearwhennot
using contraception? (Answer categories: nine or more, less then nine,
less then six, two or less); 2) Do you suffer from increased hair growth?
(Answer categories: yes, no); and 3) Do you suffer from acne/pimples?
(Answer categories: yes, no).
Furthermore, the survey provided information on date of birth,
height, weight, and smoking habits. Group characteristics are listed in
Table 1.
Statistical analyses
We used 2 tests to compare the prevalence of PCOS between female
MZtwins, femaleDZtwins, females fromopposite-sex twinpairs, sisters
of twins, and spouses of male twins. In addition, binary logistic regres-
sion analyses were used to test for confounding effects of body mass
index (BMI), age, and smoking initiation. BMI data were divided into
three categories: less than 20, 20–25, and more than 25 kg/m2. Age was
put into the model as a categorical variable, with two groups: less than
30 yr and 30–45 yr. Women over 45 yr of age were excluded from the
analyses (n  324). From the total sample of 3479, this resulted in a
sample used in these analyses of 3155 [MZ1176, DZ 647, females
of a dizygotic opposite-sex twin pair (DOS)  454, sisters of a twin 
664, and spouses214). Smoking initiationwas adichotomous variable
with two categories: yes, 1; or no, 0. Because data from twins and sin-
gleton sisters are not independent, all analyses have also been done using
a random selection of just one person per family. This resulted in a total
sample of 2343 subjects (MZ females  783, DZ females  449, DOS
females 427, sisters of a twin  466, spouses 218); after age selec-
tion, a sample of 2151 remained for these analyses (MZ  686, DZ 
406, DOS  425, sisters of a twin  420, spouses  214).
Results
Characteristics of the study population are described in Table 1.
Mean age in the PCOS group was 2 yr lower than in the non-
PCOS group. BMI and smoking status did not differ between
groups.
The prevalence of PCOS in twins (MZ, DZ, and DOS), their
sisters, and spouses of twins is reported in Table 2. A 2 test (P
0.970; df  4) showed that the PCOS prevalence between the
groupsdidnotdiffer significantly.Whencomparingonlywomen
fromMZ,DZ, andDOS twin pairs, these results are virtually the
same (2: P  0.948; df  2), indicating that there are no sig-
nificant differences in PCOS prevalence between these groups.
Analyses done with one random person per family showed al-
most the same results (2: P 0.943, df 4). A 2 test for six or
less or two or less menstruations per year in DOS, MZ, DZ
female twins, spouses of twins, and sisters of twins showed no
significant differences between these groups (P 0.278; df 4),
indicating no differences in the prevalence of severe oligomen-
orrhea or amenorrhea betweenDOS twins and the other groups.
The association between PCOS and being a female from an
opposite-sex twin pair was tested in a binary logistic regression
model with and without BMI, age, and smoking initiation as
possible confounders (Table 3). Results, both in the total and in
the random sample, indicate that being a female of an opposite-
sex twin pair is not associated with PCOS. These results are not
altered by correcting for BMI, age, or smoking status.
TABLE 2. The prevalence of PCOS within the different twins,
their sisters and spouses
PCOS Non-PCOS % PCOS
MZ twins 36 1289 2.7
Female DZ twins 21 690 3.0
Females of an opposite
sex twin
13 467 2.7
Sisters of a twin 23 722 3.1
Spouses of a twin 5 213 2.3
Total 98 3381 2.9
PCOS is defined as less then nine menstruations per year and acne or hirsutism.
TABLE 1. The characteristics of the total and random study
population
PCOS Non-PCOS Pa
Total population (n) 98 3381
Age (yr) 27.1 (9.1) 30.0 (9.8) 0.005
BMI (kg/m2) 23.0 (4.8) 22.8 (3.7) 0.645
Smoking status
Yes 38 1435
No 60 1944 0.466
Random selection (n) 65 2278
Age (yr) 25.7 (8.5) 29.7 (9.6) 0.001
BMI (kg/m2) 22.1 (4.2) 22.8 (3.7) 0.119
Smoking status
Yes 21 972
No 44 1305 0.095
a Student’s t test for age and BMI or  2 test for smoking status.
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Discussion
According to our observations, the prevalence of PCOS does not
differ significantly betweenwomen from opposite-sex or same-sex
twin pairs, singleton sisters of twins, and biologically unrelated
women (spouses of male twins). This indicates that intrauterine
hormonal environmental conditions probably do not strongly con-
tribute to the development of PCOS, provided that there are dif-
ferencesbetweenwomenfromopposite-sexanddizygotic same-sex
twin pairs in their uterine environment. With regard to the latter,
solid human data are not available except for some demographic
findings that suggest differences in androgen exposure (11).
If intrauterine exposure to androgens contributes to the de-
velopment of PCOS, these androgens are more likely to come
from the female fetus itself rather than from the male co-twin.
This is compatible with the finding that PCOS is highly heritable
as shown in Dutch twin families (10). Furthermore, there is ac-
cumulating evidence for a genetic basis of PCOS (12–19). Be-
cause offspring of PCOS mothers share some of the maternal
traits, another possible source of androgens is the mother, but
maternal androgen excess is unlikely to affect the fetus because
excessive placental aromatase activity presents as an effective
barrier (20). Recent studies show that hyperandrogenism in
women who develop PCOS may be due to polymorphisms in
the SHBG and androgen receptor genes (21). This underlines
again the genetic component that seems most important in
developing PCOS.
The prevalence of PCOS in the present study is rather low
compared with other countries where 6–10% is reported (22–
27). Nevertheless, it is in accordance with another study report-
ing a PCOS prevalence in The Netherlands of around 3–4% for
oligomenorrhea combined with hyperandrogenism (28).
This difference in prevalence between studies may be due to
characterizing the PCOS phenotype. According to the Rotter-
dam criteria, there are three possible polycystic ovary pheno-
types: 1) oligomenorrhea and hyperandrogenism; 2) oligomen-
orrhea and PCOS ovaries; and 3) hyperandrogenism and PCOS
ovaries (7). For this study, we have chosen the first phenotype to
represent a PCOS female because ultrasound data have been
shown earlier to be nonspecific, with PCOS ovaries present in as
many as 20–25% of the general population (29). Furthermore,
this phenotype is shown to be highly heritable (10), and in our
sample reliable ultrasound data were not available because data
were collected with a mailed questionnaire. One could argue
that PCOS might be difficult to diagnose with self-report data
on acne, hirsutism, and oligo- or amenorrhea, but studies by
Taponen et al. (30, 31) showed that the prevalence of PCOS
was as high as 70% in women reporting both oligo- or am-
enorrhea and hirsutism. Furthermore, the combination of
these symptoms could reliably identify women with typical
PCOS endocrine profiles (30, 31).
Age might be a possible confounder in this study because
PCOS women were significantly younger than non-PCOS
women. However, the absolute difference was less than 3 yr.
Regression analyses showed no difference in PCOS prevalence
between the different types of twins, their sisters, and spouses,
before and after correction for age. Although themean BMIwas
normal in both groups, there were obese subjects in the study
population, and therefore analyses were done with and without
correction for BMI.We have shown that the PCOS prevalence in
our population is independent of BMI.
We conclude that there are no indications that the prevalence
of PCOS is higher in females from opposite-sex twin pairs com-
paredwithwomen from same-sex twin pairs, a singleton sister of
a twin, and biologically unrelated women (spouses of male
twins). This may indicate that possible androgen overexposure
of the female fetus, caused by a shared intrauterine environment
with a male fetus, does not result in PCOS-like traits.
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TABLE 3. Results of the binary logistic regression analyses
Total population (n  3479) Random selection (n  2343)
 OR CI  OR CI
Model 1
Females from an opposite-sex twin pair 0.047 0.954 0.528–1.725 0.016 1.016 0.538–1.919
Model 2
Females from an opposite-sex twin pair 0.037 0.963 0.531–1.750 0.014 1.014 0.534–1.926
BMI group 1 0.056 0.946 0.557–1.605 0.027 1.027 0.549–1.926
BMI group 2 0.120 1.128 0.595–2.140 0.201 0.818 0.353–1.892
Age 30 yr 0.486 1.626 0.683–3.873 1.050 2.858 0.677–12.068
Age 30–45 yr 0.200 1.221 0.489–3.052 0.710 2.034 0.453–9.133
Smoking initiation 0.046 0.955 0.621–1.467 0.278 0.757 0.442–1.297
Table 3 shows the results of the binary logistic regression analyses with PCOS as the dependant variable and being a female from an opposite-sex twin pair as the
primary determinant. Model 1 indicates the crude model, model 2 is after correction for possible confounders (BMI, age, and smoking initiation). BMI is divided into
three groups (20, 20–25, and 25 kg/m2). Group 1 is used as reference. Age groups are: 1) 30 yr, and 2) between 30 and 45 yr. Smoking initiation: yes, 1; no, 0.
Results are shown for both the total population and a random selection of one person per family. OR, Odds ratio; CI, confidence interval.
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